Uday Popat, MD
Hematology · Houston, TXNPI 1609971266
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,385 of the $24,616 with a category attached, or 62.5%. 13 manufacturers reported payments, led by Daiichi Sankyo Inc. at 38.7% of the total.
Across 31 payments — averaging $794.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$10K
- Jazz Pharmaceuticals Inc.$4K
- Astellas Pharma Global Development$4K
- Rigel Pharmaceuticals, Inc.$3K
- CTI Biopharma Corp.$3K
- National Marrow Donor Program$215
- plus $458 from 7 others
Across 66 payments — averaging $65,613 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3.1M
- Incyte Corporation$931K
- Bayer$260K
- Novartis$44K
- National Marrow Donor Program$30K
What the payments were for
- Consulting fees$15,38562%
- Speaking & faculty fees$5,69523%
- Travel & lodging$2,0338%
- Food & beverage$1,5036%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 5 | $9,520 |
| Jazz Pharmaceuticals Inc. | 11 | $4,463 |
| Astellas Pharma Global Development | 1 | $4,000 |
| Rigel Pharmaceuticals, Inc. | 2 | $3,124 |
| CTI Biopharma Corp. | 2 | $2,836 |
| National Marrow Donor Program | 1 | $215 |
| Incyte Corporation | 3 | $150 |
| Karyopharm Therapeutics Inc. | 1 | $91 |
| Bristol Myers Squibb | 1 | $60 |
| Gilead | 1 | $50 |
| Novartis | 1 | $50 |
| AbbVie | 1 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,616 in reported general payments places this provider in the 80th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrevymisLetermovir | 22 | $156,110 |
| Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium | 11 | $9,288 |
| Posaconazole | 11 | $8,850 |
| ValacyclovirValacyclovir Hcl | 23 | $473 |
Paid to pharmacies, not to this prescriber.
Other hematology in Houston
- Miguel EscobarHouston$767K
- Kelty BakerHouston$229K
- Siddhartha GangulyHouston$119K
- Lawrence RiceHouston$103K
- Modupe IdowuHouston$102K
- Swaminathan IyerHouston$50K
- Jing YeHouston$34K
- Senthil SukumarHouston$31K
- Sa WangHouston$27K
- Rashmi Kanagal ShamannaHouston$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.